Strides Pharma Science Limited (Star) Share Price & Stock Analysis

Strides Pharma Science Limited (Star) (NSE: STAR, BSE: 532531) is a Bengaluru, Karnataka-based company in the Pharmaceuticals industry. With a market capitalisation of ₹9,212 Cr, it ranks #619 by market cap among the 6,197 Indian listed companies on FinBizNet, and #12 of 63 in Pharmaceuticals. At ₹1,008.70 (as of 16 Nov 2026), the share price is 20.0% below its 52-week high of ₹1,260.90 and 31.2% above its 52-week low of ₹768.65. The share price is up 7.0% over one year and up 2.6% over three months.

Key Metrics

Current Price₹1,008.70
Market Cap₹9,212 Cr
NSE SymbolSTAR
BSE Code532531
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Pharmaceuticals
P/E Ratio16.8
Return on Equity20.03%
Return on Assets6.26%
52-Week Range₹768.65 – ₹1,260.90
1-Year Price Change+7.0%
3-Month Price Change+2.6%
Beta (1Y)0.43
Dividend Yield0.49%
HeadquartersBengaluru, Karnataka
Websitewww.strides.com

Latest Quarterly Results — Q2 FY27

Revenue₹1,430 Cr
Net Profit₹134 Cr
Net Margin9.4%
EPS (Basic)₹14.19
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Strides Pharma Science Limited (Star) Quarterly Revenue and Profit Trend

Strides Pharma Science Limited (Star) reported revenue of ₹1,430 Cr in Q2 FY27, up 17.1% from ₹1,221 Cr in Q2 FY26 and up 13.0% from ₹1,265 Cr in Q1 FY27. It posted a net profit of ₹134 Cr for the quarter, against a net profit of ₹132 Cr in Q2 FY26 (up 2.0%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹1,120 Cr (Q1 FY26) to ₹1,430 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹1,430 Cr₹134 Cr9.4%
Q1 FY27₹1,265 Cr₹165 Cr13.1%
Q4 FY26₹1,323 Cr₹129 Cr9.8%
Q3 FY26₹1,195 Cr₹208 Cr17.4%
Q2 FY26₹1,221 Cr₹132 Cr10.8%
Q1 FY26₹1,120 Cr₹106 Cr9.4%
Q4 FY25₹1,190 Cr₹86 Cr7.2%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 29.00% of Strides Pharma Science Limited (Star)'s shares as of Sept 2026, against 27.86% in Sept 2025 (+1.14 percentage points). Delivery averaged 49.1% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Strides Pharma Science Limited (Star)

Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women’s health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. The company was incorporated in 1990 and is based in Bengaluru, India.

Products and Services

1. Pharmaceutical Business (Excl. Bio-Pharmaceutical Business)-This segment develops and manufactures pharmaceutical products. 2. Bio-Pharmaceutical Business-This segment engages in bio-pharmaceutical business. 3. Pharmaceutical Business-This segment develops and manufactures pharmaceutical products. 4. Biotech Business-This segment is involved in biotech business.

Business Segments

1. Pharmaceutical Business (Excl. Bio-Pharmaceutical Business)-100%

Strides Pharma Science Limited (Star) vs Peers — Pharmaceuticals

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Abbott India Ltd.₹56,531 Cr36.334.46%₹1,814 Cr-8.1%
Emcure Pharmaceuticals Ltd₹42,344 Cr47.919.57%₹2,820 Cr+73.3%
Ajanta Pharma Limited₹41,474 Cr39.425.39%₹1,794 Cr+27.8%
Piramal Pharma Ltd₹32,600 Crn/m-4.00%₹2,617 Cr+22.8%
RUBICON RESEARCH LIMITED₹28,526 Cr112.319.14%₹576 Cr+162.7%
Caplin Point Laboratories Ltdte₹18,155 Cr28.319.94%₹630 Cr+23.6%
Pfizer Ltd.₹17,811 Cr24.517.16%₹727 Cr-24.2%
Eris Lifesciences Ltd₹17,691 Cr28.318.07%₹892 Cr-17.5%
Strides Pharma Science Limited (Star)₹9,212 Cr16.820.03%₹1,430 Cr+7.0%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Strides Pharma Science Limited (Star)?

Strides Pharma Science Limited (Star) is trading at ₹1,008.70, with a market capitalisation of ₹9,212 Cr.

Which sector does Strides Pharma Science Limited (Star) belong to?

Strides Pharma Science Limited (Star) operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).

What are the key financial ratios of Strides Pharma Science Limited (Star)?

Strides Pharma Science Limited (Star) has a P/E of 16.8 and a return on equity of 20.03%.

What is the stock symbol of Strides Pharma Science Limited (Star)?

Strides Pharma Science Limited (Star) is listed on the NSE under the symbol STAR and on the BSE under the scrip code 532531.

How has Strides Pharma Science Limited (Star)'s share price moved over the past year?

Strides Pharma Science Limited (Star)'s share price is up 7.0% over one year and up 2.6% over three months. Its 52-week range is ₹768.65 to ₹1,260.90.

What were Strides Pharma Science Limited (Star)'s latest quarterly results?

In Q2 FY27, Strides Pharma Science Limited (Star) reported revenue of ₹1,430 Cr and net profit of ₹134 Cr, with basic EPS of ₹14.19 (consolidated, parsed from the company's exchange filing).

How have Strides Pharma Science Limited (Star)'s revenue and profit changed over the past year?

Strides Pharma Science Limited (Star) reported revenue of ₹1,430 Cr in Q2 FY27, up 17.1% from ₹1,221 Cr in Q2 FY26 and up 13.0% from ₹1,265 Cr in Q1 FY27.

What is the promoter holding in Strides Pharma Science Limited (Star)?

Promoters held 29.00% of Strides Pharma Science Limited (Star)'s shares as of Sept 2026, against 27.86% in Sept 2025 (+1.14 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.